Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03223103
Recruitment Status : Recruiting
First Posted : July 19, 2017
Last Update Posted : May 29, 2019
NovoCure Ltd.
Information provided by (Responsible Party):
Adilia Hormigo, Icahn School of Medicine at Mount Sinai

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 22, 2020
Estimated Study Completion Date : May 22, 2021